Prm19 - Reporting Follow-Up in Survival Analyses: Informative or Not?

Leeneman, B; Blommestein, Hedwig M.; Groot, Saskia de; Holleman, Marscha S.; Kuppen, Malou C.P.; Luyendijk, Marianne; Westgeest, HM; Groot, C Uyl de; Franken, M

doi:10.1016/j.jval.2018.09.2143

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In case it was reported, the method of computation greatly differed between the studies. Therefore, comparing reported follow-up times would be biased [38]. Nine RCTs published at least one extended follow-up publication.…”

Section: Systematic Literature Reviewmentioning

confidence: 99%

A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma

Franken

Leeneman

Gheorghe

et al. 2019

European Journal of Cancer

View full text Add to dashboard Cite

BACKGROUNDAlthough a myriad of novel treatments entered the treatment paradigm for advanced melanoma, there is a lack of head-to-head evidence. We conducted a network meta-analysis (NMA) to estimate each treatment's relative effectiveness and safety. METHODSA systematic literature review (SLR) was conducted in Embase, MEDLINE, and Cochrane to identify all phase-III randomised controlled trials (RCTs); timeframe: January 1, 2010 to March 11, 2019. We retrieved evidence on treatment-related grade 3/4 adverse events, progression-free survival (PFS), and overall survival (OS). Evidence was synthesised using a Bayesian fixed-effect NMA. Reference treatment was dacarbazine. In accordance with RCTs, dacarbazine was pooled with temozolomide, paclitaxel, and paclitaxel plus carboplatin. To increase homogeneity of the study populations, RCTs were only included if patients were not previously treated with novel treatments. RESULTSThe SLR identified 28 phase-III RCTs involving 14,376 patients. Nineteen (seventeen) treatments were included in the effectiveness (safety) NMA. For PFS, dabrafenib plus trametinib (hazard ratio [HR] PFS: 0.21) and vemurafenib plus cobimetinib (HR PFS: 0.22) were identified as most favourable treatments. Both had, however, less favourable safety profiles. Five other treatments closely followed

show abstract

Section: Systematic Literature Reviewmentioning

confidence: 99%

A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma

Franken

Leeneman

Gheorghe

et al. 2019

European Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…For the remaining studies, we sourced country-specific population estimates using a recent United Nations report (Table 2) [26]. Three studies reported stage II/III data from the USA [12,24,25] and ten studies reported stage II and/or III in seven European countries covering Denmark [15], England [16], Estonia [18], Germany [23], the Netherlands [17], Sweden [13,19,21,22] and Spain [20].…”

Section: Characteristics Of Included Incidence Studiesmentioning

confidence: 99%

“…Stage II incident cases were reported in 13 publications. We identified data from three US studies [12,24,25] and ten European studies (Table 2) [13,[15][16][17][18][19][20][21]23]. The number of incident cases were reported for a range of timeframes covering the period from 1989 to 2016, using data identified from national cancer registries and hospital records.…”

Section: Incident Cases In Stages II and Iii Melanoma Incident Cases In Stage Ii Melanomamentioning

confidence: 99%

Epidemiology and Survival Outcomes in Stages II and III Cutaneous Melanoma: A Systematic Review

et al. 2020

View full text Add to dashboard Cite

Aim: Management of cutaneous melanoma (CM) is continually evolving with adjuvant treatment of earlier stage disease. The aim of this review was to identify published epidemiological data for stages II–III CM. Materials & methods: Systematic searches of Medline and Embase were conducted to identify literature reporting country/region-specific incidence, prevalence, survival or mortality outcomes in stage II and/or III CM. Screening was carried out by two independent reviewers. Results & conclusion: Of 41 publications, 14 described incidence outcomes (incidence rates per stage were only reported for US and Swedish studies), 33 reported survival or mortality outcomes and none reported prevalence data. This review summarizes relevant data from published literature and highlights an overall paucity of epidemiological data in stages II and III CM.

show abstract

Prm19 - Reporting Follow-Up in Survival Analyses: Informative or Not?

Cited by 2 publications

References 0 publications

A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma

A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma

Epidemiology and Survival Outcomes in Stages II and III Cutaneous Melanoma: A Systematic Review

Contact Info

Product

Resources

About